Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue	$ 286,151	$ 358,586	$ 541,392	$ 770,179
Cost of goods sold	118,390	108,970	192,106	226,314
Gross margin	167,761	249,616	349,286	543,865
General and administrative expense	3,310,368	729,528	4,808,314	1,945,670
Operations expense	1,271,258	378,906	1,737,824	666,496
Sales and marketing expense	685,029	554,084	1,239,245	1,104,623
Total operating loss	(5,098,894)	(1,412,902)	(7,436,097)	(3,172,924)
Gain on revaluation of cash advances to Helomics	1,222,244		1,222,244
Other income	(3,223)		50,209
Other Expense	819,283		1,389,059
Loss on equity method investment		960,508	439,637	960,508
Gain on revaluation of equity method investment	6,164,260		6,164,260
Net income/(loss)	1,465,104	(2,373,410)	(1,828,080)	(4,133,432)
Deemed dividend on Series E Convertible Preferred Stock	20,398		20,398
Net income/(loss) attributable to common shareholders per common shares – basic and diluted	$ 1,444,706	$ (2,373,410)	$ (1,848,478)	$ (4,133,432)
Gain/(loss) per common share - basic (in dollars per share)	$ 0.05	$ (0.20)	$ (0.08)	$ (0.36)
Gain/(loss) per common share – diluted (in dollars per share)	$ 0.02	$ (0.20)	$ (0.08)	$ (0.36)
Weighted average shares used in computation - basic (in shares)	29,609,373	11,878,490	22,747,544	11,632,221
Weighted average shares used in computation - diluted (in shares)	60,070,783	11,878,490	22,747,544	11,632,221